

**Ann Lloyd CBE, Cadeirydd | Chair**

☎ 01633 435 957

✉ Ann.Lloyd@wales.nhs.uk

**Nicola Prygodzicz, Prif Weithredwr | Chief Executive**

☎ 01633 435 958 🐦 CEOabuhb

✉ Nicola.Prygodzicz@wales.nhs.uk



**GIG  
CYMRU  
NHS  
WALES**

Bwrdd Iechyd Prifysgol  
Aneurin Bevan  
University Health Board

Our ref: **FOI 23-583**

Tuesday, 30 January 2024

Thank you for your request to Aneurin Bevan University Health Board for information under the Freedom of Information Act (2000) received on 06 November 2023.

## Your request

You requested the following:

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

### Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?
  - Azacitidine monotherapy
  - Low dose cytarabine (LoDAC) monotherapy
  - Venetoclax + azacitidine
  - Venetoclax + LoDAC
  - Ivosidenib
  - Intensive chemotherapy-based regimen
  - Other
2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
  - Azacitidine monotherapy
  - Low dose cytarabine (LoDAC) monotherapy
  - Venetoclax + azacitidine
  - Venetoclax + LoDAC
  - Ivosidenib
  - Intensive chemotherapy-based regimen
  - Other

Note: this should only include patients who have started first-line treatment during the 6-month window

3. Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many received treatment in line with National Institute for Health and Care Excellence guidance?

#### Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

#### **Our response**

We have conducted a search of our records and have concluded that we are unable to provide data on how many patients received these therapies as we do not hold this information centrally. This means that we would need to search individual patient records to obtain this information. We have established that it would take in excess of 18 hours to access this information and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test.

We can however provide usage data for Haematology medications listed. This is contained in the attached spreadsheet. Please note that this data relates to May 2023-October 2023.